期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

熊去氧胆酸胶囊对黄疸型肝炎退黄的疗效观察 被引量：3

下载PDF
导出
摘要 熊去氧胆酸胶囊对黄疸型肝炎退黄的疗效是为了提高治疗黄疸型肝炎，保肝消退黄疸（简称退黄）疗效，本院于2009年2月～2010年2月熊去氧胆酸胶囊（UDCA），治疗黄疸型肝炎50例，观察期降酶退黄，改善肝功能的疗效，保肝抗炎，退黄，取得了较满意的疗效，现报道如下。
作者 阿色叶木.麦米提敏
机构地区 伊犁州新华医院
出处 《中外医学研究》 2011年第24期22-23,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH
关键词 熊去氧胆酸胶囊 黄疸型肝炎 退黄
分类号 R285 [医药卫生—中药学]
  • 相关文献

参考文献28

  • 1Jazrawi RP,De Caestecker JS,Gogginp M,et al.Kinetics of hepatic bile acid handing in cholestatic liver disease:effect of ursodeoxycholic acid.Gastroenterology,1994,106:134-142.
  • 2Poupon RE,Chretien Y,Poupon R,et al.Serum bile acids in primary billiary cirrhosis:effect of ursodeoxycholic acid therapy.Hepatology,1993,17:599-604.
  • 3Poupon RE,Balkau B,Eschwege E,et al.A multicenter,controlled trial of ursodiol for the treatment of primary billiary cirrhosis.UDCA-PBC study Group.N Engl J Med,1991,324:1548-1554.
  • 4Beuers U,Spengler U,Kruis W,et al.Ursodeoxycholic acid for treatment of primary sclerosing cholangitis:a placebo-controlled trial.Hepatology,1992,16:707-714.
  • 5Heathcote EJ,Cauch-Dudek K,Walker V,et al.The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary billiary cirrhosis.Hepatology,1994,19:1149-1156.
  • 6Lindor KD.Ursodiol for primary sclerosing cholangitis.Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid study Group.N Engl J Med,1997,336:691-695.
  • 7Medina JF,Martinez A,Vazquez JJ,et al.Decreased antion excganger immunoreactivity in the liver of patients with primary billarycirrhosis.Hepatology,1997,25:12-17.
  • 8Fickert P,Zollner G,Fuchsbichler A,et al.Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.Gastroenterology,2001,121:170-183.
  • 9Beuers U,Blizer M,Chittattu A,et al.Taurourodeoxycholic acid inserts the apical conjugate export pump,Mrp2,into canalicular membranes and stimulates organic antion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver.Hepatology,2001,33:1206-1216.
  • 10Kurz AK,Graf D,Schmitt M,et al.Tauroursodeoxycholate-induced choleresis involves p38(MAPK)activation andtranslocation of the bile salt expoetpump in rats.Gastroenterology,2001,121:407-19.

同被引文献23

  • 1吕以培,冼苏,李舒敏,李媛,刘良华.糖尿病性肝病17例临床分析[J].广西医科大学学报,2005,22(2):300-301. 被引量：6
  • 2Ohta Y,Kongo M,Kishikawa T. Effect of melatonin on changes in hepatic antioxidant enzyme activities in rats treated with alphanaphthylisothiocyanate[J].Journal of Pineal Research,2001.370-377.
  • 3Park HJ,Oh JH,Park SM. Identification of biomarkers of chemically induced hepatocarcinogenesis in rasH2 mice by toxicogenomic analysis[J].Archives of Toxicology,2011.1627-1640.
  • 4Sama C,Rusticali AG,Morselli-Labate AM. Effect of ursodeoxycholic acid on liver tests in chronic hepatitis:assessment of prognostic parameters[J].Clinical Drug Investigation,1997.192-198.
  • 5Yoshizaki K. Pathogenic role of IL-6 combined with TNF-alpha or IL-1 in the induction of acute phase proteins SAA and CRP in chronic inflammatory diseases[J].Advances in Experimental Medicine and Biology,2011.141-150.
  • 6Zhao L,Tang Y,You Z. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression[J].PLoS One,2011.e18909.
  • 7Faiola B,Peterson RA,Kimbrough CL. Acute ANIT toxicity in male IL-10 knockout and wild-type mice[J].Toxicologic Pathology,2010.745-755.
  • 8Miller AM,Wang H,Bertola A. Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice[J].Hepatology,2011.846-856.
  • 9Copaci I,Micu L,Iliescu L. New therapeutical indications of ursodeoxycholic acid[J].Romanian Journal of Gastroenterology,2005.259-266.
  • 10张学凤,郭辉.熊去氧胆酸胶囊治疗老年戊型淤胆型肝炎的临床观察[J].中国老年保健医学,2008,6(1):62-62. 被引量：15

引证文献3

二级引证文献7

中外医学研究
2011年 第24期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部